

Table SIV. Summary of treatment discontinuations that resulted in loss of drug survival

Reason for treatment discontinuation	Treatment cycles, n (%) ^a		
	Adalimumab	Etanercept	Infliximab
<4 months			
Primary ineffectiveness	15 (44.1)	24 (48)	1(14)
Loss of initial response	3 (8.8)	2 (4)	0 (0)
Adverse event	7 (20.6)	8 (16)	3 (43)
Patient wish	2 (5.9)	5 (10)	0 (0)
Switch to another biologic agent	1 (2.9)	2 (4)	1 (14)
Complete remission	1 (2.9)	4 (8)	2 (29)
Other	5 (14.7)	5 (10)	0 (0)
Total	34	50	7
≥4 months			
Primary ineffectiveness	34 (23.9)	31 (15.9)	4 (9.8)
Loss of initial response	42 (29.6)	79 (40.5)	14 (34.1)
Adverse event	10 (7.0)	19 (9.7)	4 (9.8)
Patient wish	20 (14.1)	31 (15.9)	7 (17.1)
Switch to another biologic agent	5 (3.5)	10 (5.1)	2 (4.9)
Complete remission	9 (6.3)	7 (3.6)	4 (9.8)
Other	22 (15.5)	18 (9.2)	6 (14.6)
Total	142	195	41

^aThe percentages refer to the total number of treatment cycles that were discontinued before, at or after 4 months of treatment.